Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Meridian Small Cap Growth Fund Chad Meade | “Zenas BioPharma, Inc. is developing transformative therapies for patients with autoimmune diseases. Its lead drug, Obexelimab, is currently in Phase III clinical trials and appears on track for potential approval and launch in 2027. During the quarter, the stock performed strongly following encouraging Phase II trial data. While near-term price movements are data-driven, management remains focused on long-term value creation. Multiple indications could support annual revenues exceeding $1 billion if development is successful. BSD Analysis: Zenas is an early-stage biotech focused on immunology and inflammatory diseases, where clinical differentiation drives everything. The science targets high-value pathways, but proof-of-efficacy remains the gating factor. Investors appropriately treat the equity as binary at this stage. Capital needs will persist until late-stage clarity emerges. Partnerships and trial design matter as much as underlying biology. If data is clean and differentiated, valuation can reset quickly. If not, downside is severe. This is biotech optionality, not a compounder.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Meridian Small Cap Growth Fund Chad Meade | “Zenas BioPharma advanced its Phase 3 trials for Obexelimab and secured up to $300 million in non-dilutive financing from Royalty Pharma to fund commercialization. The fund trimmed its position after share appreciation. BSD Analysis: Meridian continues to see Zenas as a high-conviction biotech position with significant asymmetric upside potential. The non-dilutive funding from Royalty Pharma materially extends cash runway into 2027, reducing capital risk while accelerating Obexelimab's path to commercialization. With Phase 3 data expected in late 2025 and peak sales potential exceeding $2B globally, the valuation upside remains meaningful. Broader pipeline assets in immunology and endocrinology add diversification and optionality.” | BULL | Q3 2025 Sep 30, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
